Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

3 terminated/withdrawn out of 21 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
12(57.1%)
Phase 2
8(38.1%)
Phase 4
1(4.8%)
21Total
Phase 1(12)
Phase 2(8)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT05349890Phase 1Active Not Recruiting

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Role: collaborator

NCT04061980Phase 2Active Not Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Role: collaborator

NCT05913388Phase 2Recruiting

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT04938609Phase 2Active Not Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Role: collaborator

NCT02422381Phase 1Active Not Recruiting

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Role: collaborator

NCT03247712Phase 1Active Not Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Role: collaborator

NCT03336606Phase 1Active Not Recruiting

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Role: collaborator

NCT04364048Phase 2Terminated

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Role: collaborator

NCT00554515Phase 2Completed

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma

Role: collaborator

NCT04987996Phase 2Withdrawn

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Role: collaborator

NCT04334967Phase 4Suspended

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Role: collaborator

NCT01862900Phase 1Completed

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

Role: collaborator

NCT02117362Phase 1Completed

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Role: collaborator

NCT02234921Phase 1Completed

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Role: collaborator

NCT01342224Phase 1Completed

Immunochemoradiotherapy in Patients With Pancreatic Cancer

Role: collaborator

NCT01909752Phase 2Completed

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Role: collaborator

NCT01700400Phase 1Completed

Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

Role: collaborator

NCT00003184Phase 1Completed

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Role: lead

NCT00091143Phase 1Completed

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Role: lead

NCT00232206Phase 2Terminated

Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

Role: collaborator